EMMA Stock Overview
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Emmaus Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.11 |
| 52 Week High | US$0.34 |
| 52 Week Low | US$0.051 |
| Beta | 1.7 |
| 1 Month Change | 32.81% |
| 3 Month Change | 42.19% |
| 1 Year Change | -65.53% |
| 3 Year Change | -91.32% |
| 5 Year Change | n/a |
| Change since IPO | -98.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMMA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 8.3% | -2.2% | -3.7% |
| 1Y | -65.5% | 11.6% | 20.5% |
Return vs Industry: EMMA underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: EMMA underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| EMMA volatility | |
|---|---|
| EMMA Average Weekly Movement | 33.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EMMA's share price has been volatile over the past 3 months.
Volatility Over Time: EMMA's weekly volatility (33%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 55 | n/a | www.emmausmedical.com |
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos’ patented IRAK4 inhibitor (KM10544) as an anti-cancer drug.
Emmaus Life Sciences, Inc. Fundamentals Summary
| EMMA fundamental statistics | |
|---|---|
| Market cap | US$7.03m |
| Earnings (TTM) | -US$4.74m |
| Revenue (TTM) | US$28.46m |
0.2x
P/S Ratio-1.5x
P/E RatioIs EMMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMMA income statement (TTM) | |
|---|---|
| Revenue | US$28.46m |
| Cost of Revenue | US$1.80m |
| Gross Profit | US$26.66m |
| Other Expenses | US$31.41m |
| Earnings | -US$4.74m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.077 |
| Gross Margin | 93.69% |
| Net Profit Margin | -16.66% |
| Debt/Equity Ratio | -85.8% |
How did EMMA perform over the long term?
See historical performance and comparison